Abiopharma

🔍 Sayad Pierre Sargis (Executive)

Company: FENNEC PHARMACEUTICALS INC. (FENC)

Report Date: 2026-03-28

Detailed Transactions and Holdings:

• Acquired 18,456 shares of Common Shares (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,456.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 171 shares of Common shares (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,627.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,052 shares of Common shares (Direct)
  Date: 2026-03-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 20,679.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 120,000 shares of Stock Options at $5.77 per share (Derivative)
  Date: 2026-03-31 | Code: A | Expires: 2036-03-31 | Exercise: 2027-03-31 | equity_swap_involved: 0 | shares_owned_after: 270,000.00 | transaction_form_type: 4 | Footnotes: F3, F4

Footnotes:

• F1: Represents settlement of PSUs that vested on March 31, 2026.
• F2: Represents shares released from restriction from shares awarded 3/28/2025.
• F3: On March 31, 2026, granted incentive stock options to purchase 120,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
• F4: One-third of the shares subject to this option may be exercised as of March 31, 2027 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of March 31, 2029, 100% of the total number of shares subject to this option shall be vested.